MorphoSys licenses HuCAL GOLD to OncoMed

By Elaine Rigoli

Tampa, Fla., June 8 - MorphoSys AG and OncoMed Pharmaceuticals, Inc. signed a license agreement on the use of MorphoSys's HuCAL technology in the research and development of human therapeutic antibodies for the treatment of various cancers, including breast, lung, colon and prostate, by targeting cancer stem cells.

Under the agreement, MorphoSys has granted OncoMed access to its proprietary antibody library, HuCAL GOLD, for use by OncoMed in its drug-discovery programs.

The two-year contract includes an option for OncoMed to develop HuCAL-derived therapeutic antibodies, according to a news release.

The agreement includes an upfront payment and annual user fees. Further financial details were not disclosed.

OncoMed is a pharmaceutical development company based in Mountain View, Calif.

Munich, Germany-based MorphoSys develops technologies for the production of synthetic antibodies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.